14th December 2023: Public PhD defence of Joakim Øverbø Hepatitis E Virus Epidemiology and Vaccine Response: Studies from Norway and Bangladesh

Joakim Øverbø
Joakim Øverbø

Congratulations to Joakim Øverbø at his public PhD defense which took place 14th December 2023 at the University of Oslo! 

He was enrolled in the PhD programme at the Institute of Clinical Medicine at Faculty of Medicine, University of Oslo with main supervisor Susanne Dudman as part of a project funded by Norwegian Research Council with co-supervisors Kathrine Stene-Johansen and Torbjørn Wisløff at Norwegian Institute of Public Health.

12th December 2023: Public PhD defence of Sara Debes Burdens of viral respiratory infection and consumption of antibiotics in Østfold, Norway

Sara Debes
Sara Debes

Congratulations to Sara Debes at her public PhD defense which took place 12th December 2023 at the University of Oslo! 

She was enrolled in the PhD programme at the Institute of Clinical Medicine at Faculty of Medicine, University of Oslo with main supervisor Susanne Dudman as part of a collaboration project with co-supervisors Christine Jonassen and Jon Birger Haug at Sykehuset Østfold and Birgitte de Blasio at Norwegian Institute of Public Health.

18th May 2023: Public PhD defence of Beatrice Pennati SARS-CoV-2 diagnosis in Covid-19 patients

Congratulations to Beatrice Pennati at her public PhD defense which took place 18th May 2023 at the University of Genova !
 
Beatrice has been researching SARS-CoV-2 diagnosis in Covid-19 patients during her project period in Italy. She also investigated various laboratory methods by the use of SARS-CoV-2 polymerase chain reaction test. The performace of various extraction-free methods were compared with the traditional extraction-based SARS-CoV-2 RT-PCR showing that the unheated extraction-free RT-PCR worked just as well as the standard. At Oslo University Hospital, Department of Microbiology, she examined the effect of Drug X against SARS-CoV-2 by using virus cell cultures. Further, results showed that for the 13,5% of faeces samples, it was possible to revive SARS-CoV-2 viable virions using the Vero-E6 cell line. 
Scroll to top